
-
Agenus Inc. NASDAQ:AGEN Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.
Location: 3 Forbes Rd, Massachusetts, 02421-7305, US | Website: www.agenusbio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
115M
Cash
40.44M
Avg Qtr Burn
-39.58M
Short % of Float
14.69%
Insider Ownership
1.31%
Institutional Own.
33.83%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Botensilimab (AGEN1181) (anti-CLTA-4) Details Cancer, Pancreatic cancer, Melanoma Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Colorectal cancer , Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapies Details Cancer, Non-small cell lung carcinoma, Solid tumor/s, Lung cancer | Phase 2 Update | |
Botensilimab (AGEN1181) + balstilimab Details Cancer, Sarcoma | Phase 1b Data readout | |
Botensilimab (AGEN1181) Details Cancer, Non-small cell lung carcinoma | Phase 1b Data readout | |
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Cancer, Ovarian cancer | Phase 1b Update | |
AGEN2373 w/ Botensilimab (AGEN1181) Details Solid tumor/s, Cancer, Melanoma | Phase 1b Update | |
AGEN1571 w/ Botensilimab (AGEN1181) & Balstilimab (AGEN2034) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
AGEN1423 (anti-CD73-TGFβ-trap bifunctional antibody) + balstilimab (anti-PD-1) Details Pancreatic cancer, Cancer | Failed Discontinued | |
Balstilimab (AGEN2034) Details Cancer, Cervical cancer | Failed Discontinued | |
Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4) Details Cancer, Cervical cancer | Failed Discontinued |